As of August 04, 2026, the three largest insider holders of PHGE are Fibrosis Foundation Cystic (TenPercentOwner, 491.08K shares), Chidozie Ugwumba (Other, 157.74K shares), James E Flynn (Director, 131.27K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| James E Flynn | - | 0 | 131,269 | 03 Mar, 2025 |
| Jonas Grossman | - | 19,617 | 0 | 17 Aug, 2021 |
| Lynne Marie Sullivan | - | 658 | 0 | 30 Jul, 2021 |
| Gbolahan Amusa | - | 13,835 | 0 | 28 Jul, 2021 |
| Russell Greig | - | 0 | 197 | 30 Jul, 2021 |
| Assaf Oron | Chief Business Officer | 1,358 | 0 | 18 Sep, 2024 |
| Jonathan Eitan Solomon | Chief Executive Officer | 6,671 | 0 | 21 Apr, 2025 |
| Merav Bassan | Chief Development Officer | 4,189 | 0 | 21 Apr, 2025 |
| Marina Wolfson | Chief Financial Officer | 3,608 | 0 | 21 Apr, 2025 |
| Alan Charles Moses | - | 263 | 0 | 30 Jul, 2021 |
| Chidozie Ugwumba | - | 0 | 157,738 | 14 Nov, 2022 |
| Fibrosis Foundation Cystic | - | 491,083 | 0 | 17 May, 2024 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 16 Mar, 2026 | Reuven Yeganeh | Common Stock, $0.0001 par value per share | A | 450,000 | $2.00 | 450,000 | I | C |
| 16 Mar, 2026 | Reuven Yeganeh | Common Stock, $0.0001 par value per share | A | 450,000 | $2.00 | 450,000 | I | C |
| 16 Mar, 2026 | Reuven Yeganeh | Common Stock, $0.0001 par value per share | A | 450,000 | $2.00 | 450,000 | I | C |
| 16 Mar, 2026 | Reuven Yeganeh | Common Stock, $0.0001 par value per share | D | 450,000 | $5.00 | 0 | I | S |
| 16 Mar, 2026 | Reuven Yeganeh | Common Stock, $0.0001 par value per share | D | 450,000 | $5.00 | 0 | I | S |
| 16 Mar, 2026 | Reuven Yeganeh | Common Stock, $0.0001 par value per share | D | 450,000 | $5.00 | 0 | I | S |
| 17 Mar, 2026 | Reuven Yeganeh | Common Stock, $0.0001 par value per share | A | 530,000 | $2.00 | 530,000 | I | C |
| 17 Mar, 2026 | Reuven Yeganeh | Common Stock, $0.0001 par value per share | A | 530,000 | $2.00 | 530,000 | I | C |
| 17 Mar, 2026 | Reuven Yeganeh | Common Stock, $0.0001 par value per share | A | 530,000 | $2.00 | 530,000 | I | C |
| 17 Mar, 2026 | Reuven Yeganeh | Common Stock, $0.0001 par value per share | D | 530,000 | $5.00 | 0 | I | S |
| 17 Mar, 2026 | Reuven Yeganeh | Common Stock, $0.0001 par value per share | D | 530,000 | $5.00 | 0 | I | S |
| 17 Mar, 2026 | Reuven Yeganeh | Common Stock, $0.0001 par value per share | D | 530,000 | $5.00 | 0 | I | S |
| 16 Mar, 2026 | Reuven Yeganeh | Series Y Convertible Preferred Stock | D | 900 | $0.00 | 1,060 | I | C |
| 16 Mar, 2026 | Reuven Yeganeh | Series Y Convertible Preferred Stock | D | 900 | $0.00 | 1,060 | I | C |
| 16 Mar, 2026 | Reuven Yeganeh | Series Y Convertible Preferred Stock | D | 900 | $0.00 | 1,060 | I | C |
| 17 Mar, 2026 | Reuven Yeganeh | Series Y Convertible Preferred Stock | D | 1,060 | $0.00 | 0 | I | C |
| 17 Mar, 2026 | Reuven Yeganeh | Series Y Convertible Preferred Stock | D | 1,060 | $0.00 | 0 | I | C |
| 17 Mar, 2026 | Reuven Yeganeh | Series Y Convertible Preferred Stock | D | 1,060 | $0.00 | 0 | I | C |
| 16 Mar, 2026 | Reuven Yeganeh | Common Stock Purchase Warrants | D | 1,300,000 | $5.00 | 2,000,000 | I | S |
| 16 Mar, 2026 | Reuven Yeganeh | Common Stock Purchase Warrants | D | 1,300,000 | $5.00 | 2,000,000 | I | S |